Transaction DateRecipientSharesTypePriceValue
4th September 2020Steven W Lefkowitz2,215Open or private purchase$3.98$8,815.70
4th September 2020Steven W Lefkowitz3,500Open or private purchase$4.00$14,000.00
3rd September 2020Matthew T David1,150Open or private purchase$4.07$4,680.50
2nd September 2020Myron Kaplan15,300Open or private purchase$4.27$65,358.54
19th August 2020Mehmood Khan9,404Open or private purchase$4.91$46,176.46
19th August 2020Mehmood Khan8,433Open or private purchase$4.90$41,295.56
18th August 2020Mehmood Khan21,082Open or private purchase$4.86$102,365.76
18th August 2020Mehmood Khan4,500Open or private purchase$4.62$20,790.00
18th August 2020Mehmood Khan2,331Open or private purchase$4.60$10,722.60
14th August 2020Jr. John L. Armstrong10,000Open or private purchase$4.16$41,600.00
Cor Medix
Cor Medix logo

Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 10/10.

CorMedix, Inc. operates as a pharmaceutical and medical device company. The firm is developing its product Neutrolin, a novel, non-antibiotic antimicrobial solution.

Ticker: CRMD
Sector: Healthcare
Industry: Biotechnology
SEC Central Index Key (CIK): 1410098
Employees: 22
Exchange: NYSE American
Auditor Opinion:

Disclosure Language changes
Analysis of subtle changes in disclosure language. Red is a sign of more constrained, less positive language changes etc. Green is more positive, less constrained etc.
Red Flags
Red Flag analysis based on Klaus Henselmann / Elisabeth Scherr paper
Fundamentals
Cash at Carrying Value: $16 M (0%)
Inventory, Net: $278 Th (0%)
Assets, Current: $24 M (-17%)
Property, Plant and Equipment, Net: $103 Th (-18%)
Assets: $24 M (-17%)
Accounts Payable, Current: $1 M (35%)
Accrued Liabilities, Current: $4 M (0%)
Liabilities, Current: $6 M (-1%)
Liabilities: $6 M (-1%)
Common Stock, Value, Issued: $26 Th (1%)
Common Stock, Shares, Issued: $26 M (1%)
Retained Earnings (Accumulated Deficit): $205 M (4%)
Accumulated Other Comprehensive Income (Loss), Net of Tax: $106 Th (8%)
Stockholders' Equity (Parent): $19 M (0%)
Liabilities and Equity: $24 M (-17%)
Gross Margin: $3 Th (-87%)
Research and Development: $6 M (-30%)
Operating Income/Loss: $9 M (-38%)
Provision for income taxes: $5 M (0%)
Red Flag analysis based on Klaus Henselmann / Elisabeth Scherr paper
News
Generic placeholder
CorMedix Inc. to Begin Trading on the Nasdaq Stock Exchange

21st January 2021